Bausch + Lomb (NYSE:BLCO – Get Free Report) and Pro-Dex (NASDAQ:PDEX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Analyst Recommendations
This is a breakdown of current recommendations for Bausch + Lomb and Pro-Dex, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bausch + Lomb | 1 | 7 | 6 | 1 | 2.47 |
| Pro-Dex | 0 | 0 | 2 | 1 | 3.33 |
Bausch + Lomb presently has a consensus price target of $19.46, suggesting a potential upside of 12.21%. Pro-Dex has a consensus price target of $74.00, suggesting a potential upside of 18.42%. Given Pro-Dex’s stronger consensus rating and higher probable upside, analysts plainly believe Pro-Dex is more favorable than Bausch + Lomb.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Bausch + Lomb | -3.21% | 4.14% | 1.93% |
| Pro-Dex | 17.62% | 25.13% | 16.02% |
Valuation & Earnings
This table compares Bausch + Lomb and Pro-Dex”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bausch + Lomb | $5.10 billion | 1.22 | -$360.00 million | ($0.48) | -36.13 |
| Pro-Dex | $77.55 million | 2.60 | $13.66 million | $4.13 | 15.13 |
Pro-Dex has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Bausch + Lomb has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.
Insider and Institutional Ownership
11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 1.4% of Bausch + Lomb shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Pro-Dex beats Bausch + Lomb on 11 of the 14 factors compared between the two stocks.
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
About Pro-Dex
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
